Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
Conditions
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- Recurrent Central Nervous System Lymphoma
- Refractory Central Nervous System Lymphoma
Interventions
- DRUG: Ibrutinib
- BIOLOGICAL: Nivolumab
Sponsor
M.D. Anderson Cancer Center
Collaborators